Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
Primary Purpose
Cystic Fibrosis, Liver Fibrosis
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Fibroscan
Sponsored by
About this trial
This is an interventional diagnostic trial for Cystic Fibrosis focused on measuring cystic fibrosis, elastography, liver biopsy
Eligibility Criteria
Inclusion Criteria:
- Verified cystic fibrosis
Exclusion Criteria:
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Elastography
Arm Description
Fibroscan elastography device for evaluation of liver disease in CF patients.
Outcomes
Primary Outcome Measures
Elastographic Value in kPa Measured by Fibroscan
Elastographic values given in kPa by Fibroscan. All patients undergo elastographic measurement of the liver and ultrasound of the liver. The grade of fibrosis is to be established by setting the cut-off for cystic fibrosis patients.
Secondary Outcome Measures
Full Information
NCT ID
NCT02603666
First Posted
May 4, 2015
Last Updated
November 1, 2016
Sponsor
Karolinska University Hospital
Collaborators
Karolinska Institutet
1. Study Identification
Unique Protocol Identification Number
NCT02603666
Brief Title
Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
Official Title
Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
June 2014 (Actual)
Study Completion Date
June 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Karolinska University Hospital
Collaborators
Karolinska Institutet
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of the study is to find CF patients at risk for cystic fibrosis related liver disease (CFLD). Comparison of ultrasound by two modalities and biochemical markers with histological evaluation of liver biopsy if present.
Detailed Description
There are 209 CF patients attending Stockholm Cystic Fibrosis Center (January 2010). All up till 15 years of age are screened for liver disease annually by ultrasound (US) and also by biochemical markers. Ultrasound is performed every third year over 15 years of age in patients without CFLD, while all of them with diagnosed CFLD are continued to be investigated annually. Biochemical markers are controlled at least once every year in all CF patients. Elastography of the liver will be planned together with the investigations of the annual follow up, in an optimal clinical status. If either US or elastography of the liver indicates liver disease or progress of the already existing pathological changes, a liver biopsy will be performed according to routine procedure at Stockholm CF Centre. Also, historical data of liver biopsies and biochemical investigations will be considered in the study.
Elastography of the liver will be performed by Fibroscan device, with transducers for children and adults, respectively.
Clinical importance Liver US investigations in CF patients have important implications but are difficult to standardize in a routine clinical setting. Elastography may have an advantage in the evaluation of early fibrosis with clinical importance in pursuing diagnostics and intensifying treatment. A significant group (up to 25 %) of CF patients may be helped by this novel method. Including histological data, accuracy of elastography in CF patients may be improved. Further details of the importance of fatty acid status in CF may be elucidated.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystic Fibrosis, Liver Fibrosis
Keywords
cystic fibrosis, elastography, liver biopsy
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
130 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Elastography
Arm Type
Other
Arm Description
Fibroscan elastography device for evaluation of liver disease in CF patients.
Intervention Type
Device
Intervention Name(s)
Fibroscan
Other Intervention Name(s)
Elastography
Intervention Description
Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.
Primary Outcome Measure Information:
Title
Elastographic Value in kPa Measured by Fibroscan
Description
Elastographic values given in kPa by Fibroscan. All patients undergo elastographic measurement of the liver and ultrasound of the liver. The grade of fibrosis is to be established by setting the cut-off for cystic fibrosis patients.
Time Frame
Within 28 days in connection with their annual evaluation at a single point of time
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Year
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Verified cystic fibrosis
Exclusion Criteria:
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ferenc Karpati, MD, PhD
Organizational Affiliation
Stockholm CF Center, Karolinska University Hospital
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
We'll reach out to this number within 24 hrs